After closing crowdfunding round, Houston biotech co. FibroBiologics reconsiders IPO route

A successful crowdfunding round has led a Houston biotech company to revisit the idea of going public after turning away from the option last year.

FibroBiologics, a clinical-stage company specializing in cell therapy using a type of cell known as a fibroblast, closed its crowdfunding round in early April after launching the round on the platform StartEngine in January. The round hit nearly $5 million with 718 investors, according to the company’s offering page on StartEngine.

FibroBiologics…